Table S2.
Prognostic value of ABCC5 protein expression for the biochemical recurrence-free survival in univariate and multivariate analyses by Cox regression
| Covariant | Univariate analysis
|
Multivariate analysis
|
||||
|---|---|---|---|---|---|---|
| Exp (B) | 95% CI | P-value | Exp (B) | 95% CI | P-value | |
| ABCC5 protein | 3.128 | 1.187–8.239 | 0.021 | 3.411 | 1.158–10.047 | 0.026 |
| Gleason score | 2.338 | 1.091–5.011 | 0.029 | 2.551 | 1.030–6.318 | 0.043 |
| Preoperative PSA | 1.432 | 0.955–2.1146 | 0.082 | |||
| Age | 2.317 | 0.806–6.664 | 0.119 | |||
| Angiolymphatic invasion | 1.327 | 0.877–2.009 | 0.181 | |||
| Surgical margin status | 1.331 | 0.946–1.873 | 0.101 | |||
| PCa stage | 2.594 | 1.382–4.869 | 0.003 | 1.325 | 0.961–1.827 | 0.086 |
| Lymph node metastasis | 3.126 | 1.110–8.805 | 0.031 | 3.151 | 1.207–8.222 | 0.019 |
| Seminal vesicle invasion | 2.438 | 0.905–6.568 | 0.078 | |||
Abbreviations: PCa, prostate cancer; PSA, prostate-specific antigen.